| Literature DB >> 32983550 |
Jonathan Doenges1, Elisabeth Kuckuck1, Werner Cassel1, Olaf Hildebrandt1, Andreas Weissflog2, Keywan Sohrabi3, Niklas Koehler3, Volker Gross3, Timm Greulich1, Ulrich Koehler1.
Abstract
INTRODUCTION: The Global Initiative for Asthma (GINA)-defined criteria for asthma control include questions about daytime symptoms, limitation of activity, nocturnal symptoms, need for reliever treatment and patients' satisfaction. Patients with nocturnal symptoms like wheezing and cough often suffer from lower sleep quality and impaired daytime performance. The lack of an appropriate method for standardized and objective monitoring of respiratory symptoms leads to difficulties in asthma management. The aim of this study is to present a new method for automated wheeze and cough detection during sleep and to assess the actual level of asthma control by the Asthma Control Test (ACT).Entities:
Keywords: Asthma; Asthma control test; Cough; Long-term monitoring of respiratory sounds; Wheezing
Year: 2020 PMID: 32983550 PMCID: PMC7513478 DOI: 10.1186/s40733-020-00062-w
Source DB: PubMed Journal: Asthma Res Pract ISSN: 2054-7064
Fig. 1a LEOSound-recorder with three body microphones (labelled 1) and one ambient microphone (labelled 2). b Illustration of the recorder and microphone placement during the observation. The figure depicts one tracheal microphone and two bronchial microphones [11]
Fig. 2The user interface of the LEOSound-Analyzer is divided into two major fields - shown as Event Screen and Epochal View. The Event Screen displays the breathing rate (blue line), the detected coughing events (green) and the wheezing rate (red) of the associated epoch. In the Epochal View the selected epochs from the Event Screen are displayed as a spectrogram. Optionally, the epochs can be represented as a loudness level
Anthropometric data of study cohort (n = 55)
| n/N or Average ± SD | Min - Max | |
|---|---|---|
| Sex [% female] | 37/55 (67.3) | |
| Age [years] | 41.0 ± 13.7 | 20–67 |
| Weight [kg] | 78.9 ± 21.2 | 51–136 |
| Height [cm] | 172 ± 12 | 154–200 |
| BMI [kg/m2] | 26.5 ± 6.1 | 17.4–47.1 |
| Smoker [PY] | 1.8 ± 3.2 | 0–10 |
Medication used within the study cohort
| Medication | n/N (%) |
|---|---|
| ICS/LABA | 37/55 (67,3) |
| ICS solo | 7/55 (12,7) |
| LAMA | 8/55 (14,5) |
| SABA | 39/55 (70,9) |
| SAMA | 4/55 (7,3) |
| Omalizumab | 3/55 (5,5) |
| Montelukast | 7/55 (12,7) |
| Mepolizumab/Benralizumab | 3/55 (5,5) |
Differences between anthropometric data, and parameters of LEOSound-monitoring depending on ACT status
| ACT – 1 ( | ACT – 2 ( | ACT – 3 ( | |||||
|---|---|---|---|---|---|---|---|
| Median | Min – Max | Median | Min – Max | Median | Min - Max | ||
| Collective of patients | |||||||
| Age | 34 | 20–63 | 38 | 23–67 | 55.5 | 30–67 | |
| Height | 172.5 | 154–200 | 167 | 159–195 | 163.5 | 156–196 | 0.217 |
| Weight | 76.5 | 52–131 | 70 | 51–136 | 78.5 | 55–135 | 0.752 |
| BMI | 24.8 | 17.4–36.7 | 23.7 | 18.7–47.1 | 26.7 | 21.8–40.8 | 0.443 |
| PY | 0 | 0–10 | 0 | 0–10 | 1 | 0–8 | 0.389 |
| ACT | 22 | 21–25 | 18 | 16–20 | 14 | 10–15 | |
| LEOSound | |||||||
| Median | Min – Max | Median | Min - Max | Median | Min - Max | ||
| Cough epoch /hour | 0 | 0–0.8 | 0.1 | 0–1.8 | 0.6 | 0–4.8 | |
| Abs Quantity coughs | 0 | 0–5 | 3 | 0–28 | 10 | 0–275 | 0.051 |
| Quantity of cough /h | 0 | 0–25 | 0.4 | 0–3.5 | 1.3 | 0–34.4 | |
| Wheezing phases | 0 | 0–1 | 0 | 0–3 | 0.5 | 0–5 | |
| Wheez. epoch/hour | 0 | 0–1 | 0 | 0–7.6 | 0.8 | 0–7.3 | |
| Wheez. durat. [min] | 0 | 0–8.9 | 0 | 0–30.5 | 3 | 0–29 | |
| Wheez. duration [%] | 0 | 0–0.9 | 0 | 0–8.1 | 0.8 | 0–6.5 | |
Statistically significant p-values are bold
Differences between anthropometric data, ACT scores and LEOSound-monitoring in patients with and without wheezing
| No wheezing ( | Wheezing ( | ||||
|---|---|---|---|---|---|
| Median | Min – Max | Median | Min – Max | ||
| Collective of patients | |||||
| Age [years] | 37 | 20–67 | 54 | 38–67 | |
| Height [cm] | 171 | 154–200 | 164 | 156–182 | 0.25 |
| Weight [kg] | 76 | 51–136 | 75 | 55–135 | 0.94 |
| BMI [kg/m2] | 24.9 | 17.4–47.1 | 25.1 | 22.0–40.8 | 0.38 |
| Pack years | 0 | 0–10 | 0,5 | 0–8 | 0.58 |
| ACT | 21 | 11–25 | 14 | 10–22 | |
| LEOSound-Monitor | |||||
| Median | Min. – Max. | Median | Min. – Max. | ||
| Cough-Epochs per hour | 0.1 | 0–1.8 | 0.3 | 0–4.8 | 0.25 |
| Abs. quantity of coughs | 1 | 0–63 | 3 | 0–175 | 0.33 |
| Quantity of coughs p. hour | 0.1 | 0–7.9 | 0.4 | 0–34.4 | 0.33 |
| Wheezing-Phases | 0 | 0–0 | 2.0 | 1.0–5.0 | – |
| Wheezing-Epochs per hour | 0 | 0–0 | 2.4 | 1.0–7.4 | – |
| Wheezing duration [min] | 0 | 0–0 | 9.5 | 4.0–30.5 | – |
| Wheezing duration [%] | 0 | 0–0 | 2.4 | 0.9–8.1 | – |
Statistically significant p-values are bold
Fig. 3Nocturnal wheezing and ACT-grouped patients
Fig. 4Coughing and non-coughing patients in ACT-groups
Summary of anthropometric data, ACT scores and LEOSound-monitoring in patients with and without coughing
| No coughing ( | Coughing ( | ||||
|---|---|---|---|---|---|
| Median | Min – Max | Median | Min – Max | ||
| Collective of patients | |||||
| Age | 33 | 23–63 | 46 | 20–67 | 0.06 |
| Height | 170 | 154–200 | 172 | 156–196 | 0.85 |
| Weight | 78 | 54–136 | 76 | 51–131 | 0.83 |
| BMI | 25.7 | 19.1–47.1 | 24.5 | 17.4–40.2 | 0.77 |
| Pack years | 0 | 0–10 | 0.5 | 0–10 | 0.38 |
| ACT | 22 | 14–25 | 20 | 10–25 | 0.06 |
| LEOSound-Monitor | |||||
| Median | Min. – Max. | Median | Min. – Max. | ||
| Cough-epochs per hour | 0 | 0–0 | 0.4 | 0.1–4.8 | – |
| Absolute quantity of coughs | 0 | 0–0 | 7.0 | 1–275 | – |
| Quantity of coughs per hour | 0 | 0–0 | 0.9 | 0.1–34.4 | – |
| Wheezing-Phases | 0 | 0–3 | 0 | 0–5 | 0.59 |
| Wheezing-Epochs per h | 0 | 0–7.6 | 0 | 0–7.3 | 0.66 |
| Wheezing duration [min] | 0 | 0–30.5 | 0 | 0–29.0 | 0.66 |
| Wheezing duration [%] | 0 | 0–8.1 | 0 | 0–6.5 | 0.68 |